Stryker Corporation - SYK STOCK NEWS

Stryker (NYSE:SYK) announced it will report financial results for the second quarter of fiscal year 2024 on Tuesday, July 30, 2024. The announcement will be made through a press release at approximately 4:05 pm ET, which will be accessible on Stryker's Press Releases page. The results will cover the company's performance for the quarter ending June 30, 2024.

Additionally, Stryker will host a webcast to discuss these results at 4:30 pm ET on the same day. The webcast will be available on Stryker's Events & Presentations page, and an archive will be accessible two hours post the live call.

Stryker has partnered with IRCAD North America, part of Atrium Health, to create an advanced surgical training center in Charlotte, NC. As part of a multi-year agreement, Stryker will supply cutting-edge medical devices and technologies to the center. Scheduled to open in summer 2025, IRCAD NA will serve as a hub for medical professionals worldwide. The center will leverage robotics, virtual and augmented reality, and artificial intelligence for surgical training. The collaboration aims to enhance medical education and patient care, aligning with Stryker’s mission to improve healthcare. The Pearl, an innovation district where IRCAD NA will be located, will also feature a new campus of Wake Forest University School of Medicine, fostering further advancements in medical science.

Stryker (NYSE:SYK) has launched the LIFEPAK 35, an advanced monitor/defibrillator aimed at supporting emergency responders and healthcare professionals. Unveiled on June 4, 2024, the device is designed to reduce caregiver burden and streamline workflow. It features a modern, intuitive platform, a slim and ergonomic design, and a large touch screen for a customizable clinical experience. The LIFEPAK 35 enables real-time access to important patient information, thereby enhancing patient care. It also offers trend monitoring and configurable events, aiding in clinical decision-making. The device is the result of over ten years of research and feedback from global customers.

Stryker (NYSE: SYK), a leader in medical technologies, has signed a definitive agreement to acquire Artelon, a company specializing in soft tissue fixation products. This acquisition aims to enhance Stryker's offerings in foot and ankle and sports medicine procedures, complementing its existing product range. Artelon's synthetic technology, designed for ligament and tendon reconstruction, has seen over 60,000 implantations worldwide. This move positions Stryker competitively in the segment, promising innovative biomaterial technology that aids soft tissue healing. The deal is subject to customary closing conditions, with both companies operating separately until then.

Stryker (NYSE:SYK) has completed the first European surgeries using its Gamma4 Hip Fracture Nailing System in Switzerland and France. The system, which treats hip and femur fractures, uses a design based on Stryker's extensive SOMA database. After obtaining CE certification in November 2023, it has been used in over 25,000 cases in North America and Japan.

Following the European debut, over 35 additional surgeries have been completed across several countries. A live broadcast event on June 4, 2024, in Germany will feature insights and case discussions led by esteemed faculty from across Europe.

Stryker (NYSE:SYK) has declared a $0.80 per share quarterly dividend payable on July 31, 2024, to shareholders of record on June 28, 2024. This represents a 6.7% increase from the prior year.

Stryker (NYSE: SYK) successfully completed the first European surgeries using the Infinity Total Ankle System with Adaptis and Everlast technology. The system is designed for efficient and accurate implementation, with positive outcomes in end-stage ankle arthritis patients. The company aims to enhance collaboration with surgeons through innovation and commitment to research.

Stryker reported strong operating results for the first quarter of 2024, with a 9.7% increase in net sales to $5.2 billion, 10% organic net sales growth, and a 33.1% increase in reported EPS. The company's MedSurg and Neurotechnology segment saw a 11.5% increase in net sales, while Orthopaedics and Spine segment reported a 7.5% increase. Adjusted operating income margin increased to 21.9%, and adjusted EPS rose by 16.8%. Stryker expects full year 2024 organic net sales growth in the range of 8.5% to 9.5%, with adjusted net earnings per diluted share projected to be between $11.85 to $12.05.